- Home
- CDTG vs CALC Comparison
CDTG vs CALC Comparison
Compare CDTG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- CALC
- Stock Information
- Founded
- CDTG 2012
- CALC 2011
- Country
- CDTG China
- CALC United States
- Employees
- CDTG N/A
- CALC N/A
- Industry
- CDTG
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- CALC Health Care
- Exchange
- CDTG NYSE
- CALC Nasdaq
- Market Cap
- CDTG 24.5M
- CALC 26.7M
- IPO Year
- CDTG 2024
- CALC N/A
- Fundamental
- Price
- CDTG $0.84
- CALC $1.67
- Analyst Decision
- CDTG
- CALC Strong Buy
- Analyst Count
- CDTG 0
- CALC 3
- Target Price
- CDTG N/A
- CALC $16.33
- AVG Volume (30 Days)
- CDTG 723.4K
- CALC 16.3K
- Earning Date
- CDTG 05-15-2025
- CALC 08-11-2025
- Dividend Yield
- CDTG N/A
- CALC N/A
- EPS Growth
- CDTG N/A
- CALC N/A
- EPS
- CDTG 0.14
- CALC N/A
- Revenue
- CDTG $29,765,205.00
- CALC N/A
- Revenue This Year
- CDTG N/A
- CALC N/A
- Revenue Next Year
- CDTG N/A
- CALC N/A
- P/E Ratio
- CDTG $5.97
- CALC N/A
- Revenue Growth
- CDTG N/A
- CALC N/A
- 52 Week Low
- CDTG $0.52
- CALC $1.43
- 52 Week High
- CDTG $4.64
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- CALC 45.93
- Support Level
- CDTG N/A
- CALC $1.68
- Resistance Level
- CDTG N/A
- CALC $1.79
- Average True Range (ATR)
- CDTG 0.00
- CALC 0.08
- MACD
- CDTG 0.00
- CALC -0.00
- Stochastic Oscillator
- CDTG 0.00
- CALC 34.48
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.